Where to find us
About UCB Ventures
- UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases.
- We invest in innovative therapeutics and technology platforms that are early stage and higher risk, in areas adjacent to or even beyond UCB's therapeutic focus on neurology/neurodegenerative diseases, immunology and muscular skeletal/bone health.
- Our team initially made four fund-to-fund investments in selected Healthcare Venture Funds in 2017, and is now focused on long term, direct investments in the US and Europe. Our first direct investment is in StrideBio, a US-based gene therapy company, with several more investments to come in the near future.
Locana Raises $55 Million Series A Financing to Advance Portfolio of RNA-targeting Gene Therapies
San Diego, 22 May 2019. — Locana, Inc., a leading RNA-targeting gene therapy company, announced today the close of a $55 million Series A financing led by ARCH Venture Partners with participation from Temasek and Lightstone Ventures, all existing investors. New investors include UCB Ventures and GV (formerly Google Ventures). Proceeds will be used to advance and expand Locana's pipeline of RNA-targeting gene therapy programs, further extend capabilities of the Locana platform technology, and assemble a premier leadership team.read more